DEDmitriy Olegovich Efremov

Dmitriy Olegovich Efremov

*This is an algorithmically generated author record based on publicly available information.

Dmitriy Olegovich Efremov has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Severe course of leptospirosis: A case report

    by Dmitriy O. Efremov, Ainur R. Khuramshin, Vladimir B. Beloborodov, Хурамшин Айнур Разифович

    This study describes a clinical case of severe leptospirosis. Patient K., was admitted to the neurosurgical department on November 26, 2023, with a diagnosis of “Closed craniocerebral injury dated 22.11.2023. Severe brain injury. Linear fracture of the occipital bone. Eyelid hematoma. An abrasion of the upper eyelid on the right.” On November 29, 2023, an objective examination drew attention to an increase in body temperature to 39.5°C, subictericity of the sclera and skin, and conjunctival injections. Hemorrhagic rash appeared on the skin of the trunk and limbs. The hemodynamics was unstable, with episodes of arterial hypotension. Laboratory examination revealed mild anemia, signs of hepatic–renal insufficiency, hyperbilirubinemia, and increased concentrations of creatine phosphokinase, C-reactive protein, and procalcitonin. Fluctuations in hepatic–renal insufficiency and levels of creatine phosphokinase and procalcitonin increased. In addition, the differential diagnostic search aimed at identifying the following infectious diseases: hemorrhagic fever with renal syndrome, leptospirosis, malaria, and viral hepatitis. IgM to Leptospira interrogans were detected (December 11, 2023). The patient received antibacterial therapy, extracorporeal detoxification, artificial ventilation, infusion therapy, and correction of the hemostasis system. With the complex treatment, the patient’s condition stabilized, and the patient was discharged from the hospital on the 61st day with restoration of health.

  • Open Access

    Mixed infection with COVID-19 and tropical malaria (case report)

    by Dmitriy Olegovich Efremov, Ainur Razifovich Khuramshin, Sergey S. Кozlov, Nikolay Ivanovich Gulyaev, A A Prokhorchik, Прохорчик Александр Александрович

    This article describes a clinical case of mixed infection with COVID-19 and tropical malaria. Patient Z., 37 years old, arrived from the Central African Republic with a diagnosis of New coronavirus infection COVID-19, confirmed (PCR RNA SARS-CoV-2+ from January 27, 2022) mild form. During an objective examination, the subictericity of the sclera and skin integument attracted attention. During thermometry, an increase in body temperature to 39.0C was found. Consciousness at the level of somnolence was observed. Hemodynamics was unstable, with episodes of arterial hypotension; heart rate was 96 beats per minute. Respiratory rate was 24 breaths in 1 minute, SpO2 95%, and with inspiratory dyspnea. According to the patients laboratory study results, severe thrombocytopenia, apparent signs of hepatic and renal insufficiency, hyperbilirubinemia, increased concentrations of C-reactive protein, and procalcitonin were revealed. A differential diagnostic search was performed between acute viral hepatitis and malaria. Blood microscopy revealed young trophozoites of Plasmodium falciparum (++++) using the thick drop method. Antimalarial therapy with Malacur was prescribed, which was then replaced with parenteral Quinine followed by mefloquine. In parallel, extracorporeal detoxification operations were performed. The patients condition was stabilized against adequate etiotropic therapy and complex intensive care measures. On the 40th day, the patient was discharged restored health. The purpose of demonstrating a clinical case is to attract increased attention to the problem of imported cases of malaria, which, when combined with COVID-19 infection, may remain unrecognized for a long time, especially in cases where the diagnosis of COVID-19 receives rapid laboratory confirmation. Adequate and timely antimalarial therapy, including a complex of intensive care measures supplemented with extracorporeal detoxification methods, is the basis for a successful outcome in patients with severe malaria with the development of severe complications.

  • A method for predicting the effectiveness of glucocorticoid therapy in patients with moderate COVID-19 based on simple clinical and laboratory data

    by Dmitry O. Efremov, Vladimir B. Beloborodov

    BACKGROUND: In patients hospitalized with coronavirus infection (COVID-19), methods for predicting the effectiveness of anti-inflammatory therapy have important practical implications for optimizing treatment and outcomes. To date, several indicators of COVID-19 patients (age, comorbidities, and laboratory criteria for the intensity of inflammation) have been identified to indicate a high probability of a severe course and a risk of an adverse outcome. However, the problem of predicting the effectiveness of anti-inflammatory therapy in patients with moderate COVID-19 is not well understood. AIM: This study aimed to develop a predictive model to determine the effectiveness/failure of anti-inflammatory therapy with glucocorticosteroids (GCS) in patients with moderate COVID-19 to improve the treatment outcomes of hospitalized patients. MATERIALS AND METHODS: This study retrospectively analyzed electronic medical record data of all patients admitted consecutively from October 1, 2020, to January 31, 2021. The study included 71 patients with probable (clinically confirmed) and confirmed (laboratory) COVID-19 of moderate course, with characteristic changes in the lungs according to computed tomography of the chest organs (CT-CCT). Given the severity of the course, all study patients were prescribed GCS in accordance with the current version of the Interim Guidelines of the Ministry of Health of the Russian Federation. RESULTS: A total of 71 patients were studied, and 53 (74.7%) of them did not require an escalation of anti-inflammatory therapy, which is regarded as an effective use of corticosteroids as an anti-inflammatory therapy (group 1). In the remaining 18 patients, the use of corticosteroids for an average of 5.5 (36) days did not have a definite clinical effect and required the additional use of monoclonal antibodies (MCA) to interleukin-6 (IL-6) or to its receptor (group 2). Using logistic regression analysis and receiver operating characteristic analysis, a mathematical model was developed and evaluated to predict the outcome of anti-inflammatory corticosteroid therapy in patients with moderate COVID-19. As risk factors, indicators that had significant differences in the studied groups before GCS initiation were selected: number of lymphocytes, platelets, and body temperature. The quality of the constructed model is assessed as very good, and the optimal cutoff point is 0.697. The sensitivity index of the model is 81.1%, and the specificity index is 72.2%. CONCLUSIONS: The mathematical model makes it possible to predict the effectiveness of GCS therapy according to the number of lymphocytes, platelets, and body temperature. The mathematical model is adequate and has a high sensitivity and specificity.

  • Open Access

    The role and place of pathogenetic therapy with glucocorticosteroid hormones in the treatment of patients with novel coronavirus infection (COVID-19)

    by Dmitrii O. Efremov, Vladimir B. Beloborodov

    In December 2019, in Wuhan (PRC), there was an outbreak of a new coronavirus infection (COVID-19) caused by coronavirus type 2 (SARS-CoV-2), which has a zoonotic origin. The World Health Organization announced the COVID-19 pandemic on March 11, 2020. In most cases, the disease is asymptomatic or mild. However, up to 15% of patients require hospitalization, and 5% develop a critical condition. To date, no effective antiviral drug COVID-19 has been found that can reduce mortality. Pathological changes in the lungs are manifested by diffuse alveolar damage, which is clinically manifested by increasing respiratory failure, accompanied by a decrease in saturation and oxygen concentration in arterial blood. It is assumed that autoimmune reactions play an important role in the development of multiple organ failure. Generalized inflammation is characterized by an increase in the concentration of C-reactive protein, ferritin, interleukin-1 and interleukin-6, and other markers. At the stage of development of infection in the form of a cytokine storm, proinflammatory cytokines can themselves become pathogenetic factors in the development of critical conditions, multiple organ failure and deaths. Therefore, a key challenge in treating hospitalized patients with COVID-19 is to control generalized inflammation. Glucocorticosteroid hormones (GCS) are widely used as anti-inflammatory drugs in the clinic of infectious diseases. However, until recently, there was no convincing data on the effectiveness of GCS in patients with COVID-19. Recently published results of a large randomized clinical trial (RECOVERY) showing the efficacy of GCS (dexamethasone) in the treatment of critically ill patients with COVID-19. At the same time, the feasibility and effectiveness of GCS in patients with COVID-19 outside critical conditions, the pathogenetic mechanisms that determine the effectiveness/ineffectiveness of these drugs and the validity of their use remain insufficiently studied.


  • Efficacy of corticosteroids in treatment of hospitalized patients with novel coronavirus infection (COVID-19)

    by Efremov D.O. Efremov, Beloborodov V.B. Beloborodov, Kovalev I.A. Kovalev, Meshkov A.V. Meshkov, Krasnogorsk A.A. Vishnevsky 3Rd Central Military Clinical Hospital Of The Ministry Of Defense Of Russia, Moscow Russian Medical Academy Of Continuing Professional Education Of The Ministry Of Healthcare Of Russia

  • Use of corticosteroid hormones in patients with moderate COVID-19: what goals can be achieved

    by Dmitry O. Efremov, Vladimir B. Beloborodov, Andrey V. Meshkov

    BACKGROUND: There is strong evidence of the effectiveness of glucocorticoids (dexamethasone) in the treatment of critically ill patients with COVID-19. However, the condition of most of them, at the time of hospitalization, is not assessed as severe or critical, but at the same time, with dynamic observation, it may worsen. It is in this group of patients that data on the effectiveness of glucocorticoids use remain few and contradictory. AIMS: to study the relationship between the use of a short course of corticosteroid hormones (CSH) in recommended doses and clinical and laboratory parameters of generalized inflammation in patients with a moderate course of new coronavirus infection (COVID-19) in a hospital setting. MATERIALS AND METHODS: The study included 121 patients with probable (clinically confirmed) and confirmed (laboratory) cases of COVID-19. A retrospective analysis of the data of electronic medical records of all patients admitted sequentially from October 1, 2020 to January 31, 2021 was carried out. The demographic indicators, comorbidities, symptoms, clinical indicators, results of laboratory tests and computed tomography were studied. Statistical analysis was performed using the standard Statistica 10 software for Windows. RESULTS: The data of electronic medical records of 121 patients were studied. Glucocorticoids were prescribed to 71 patients (58.7%), most often dexamethasone was used 70 out of 71 (98.5%). 73 (60.3%) patients had concomitant chronic diseases. 114 (94.2%) were discharged with recovery. patients, died ― 5 (4.1%), the cause of deaths was multiple organ failure. When evaluating groups of patients, in the period before the appointment of glucocorticoids and a similar period of illness in those who did not receive glucocorticoids significant differences were found in the groups in terms of generalized inflammation (body temperature, C-reactive protein concentration), indicators of respiratory disorders (respiration rate, oxygen saturation), according to indicators of the cellular composition of blood (lymphopenia and thrombocytopenia) in patients treated with glucocorticoids. After completing the course of glucocorticoids, patients showed a statistically significant increase in lymphocytes ― by 76.9%, platelets ― by 67.4%. The level of C-reactive protein significantly decreased by more than 4 times. The obtained data show a decrease in the severity of generalized inflammation, correction of the activation syndrome. acrophages, activation of bone marrow germs and positive clinical and laboratory dynamics of COVID-19. CONCLUSION: The study demonstrated reliable data on a decrease in the activity of generalized inflammation after the use of a short course of corticosteroid hormones in recommended doses. This led to the stabilization of the state in 53 of 71 (73%) patients and the termination of the escalation of further treatment.

  • Open Access

    Cytomegalovirus infection in patients after orthotopic liver transplantation (clinical report)

    by D. O. Efremov, O. A. Gerasimova, K. V. Kozlov, I. A. Gabdrakhmanov, K. V. Zhdanov

    Цитомегаловирусная инфекция после ортотопической трансплантации печени (клинический случай)